Cervical vaccine for anal cancer

A vaccine routinely used to shield against cervical cancer caused by the human papillomavirus also reduces women's risk of anal cancer, a study published by the journal The Lancet Oncology says.

The trial involved 4,210 healthy women aged 18-25 in Costa Rica, who were randomly assigned the human papillomavirus (HPV) vaccine Cervarix or an ordinary hepatitis A vaccine as a comparison.

Four years later, the women were tested for cervical and anal infections by the 16 and 18 types of HPV, which are notoriously associated with cancer.

Women who received Cervarix had a 76% lower risk of cervical infection and a 62% lower risk of anal infection compared with un-inoculated counterparts.

Anal sex could be anal cancer cause

The protection was even higher in a sub-group of women who most probably had no previous exposure to HPV. In this category, the vaccine was nearly 89% protective against cervical infection by the two viral strains and nearly 84% against anal infections.

Even though anal cancer is rare – just two cases per 100,000 people per year in the overall population, according to some estimates – women generally have twice the incidence of this disease than men.

Why this is so is unclear, although receptive anal intercourse may be a factor.

A condition called cervical neoplasia may also predispose women to the risk of anal HPV infection, regardless of anal intercourse.

Gays a higher risk

Within the general population, higher-risk groups for anal cancer are men who have sex with men. HIV-negative gays have 40 cases per 100,000 individuals per year, and HIV-infected gays 80 per 100,000.

HPV causes most anal cancers, previous research has found. Nearly four out of every five HPV-linked anal cases are caused by types 16 or 18.

In a commentary also carried by The Lancet Oncology, US specialists Diane Harper and Stephen Vierthaler of the University of Missouri-Kansas City School of Medicine, said the cost benefits of HPV vaccination for anal cancer were hazy.

Vaccine efficiency should last for years

The big question was how long the vaccine remained effective, they said.

"Without duration of efficacy of at least 15 years, cancers will not be prevented for women or men who have sex with men, only postponed," the pair noted.

Efficacy trials are lacking and anal cancer incidence is rare. Let's use our resources wisely.

(Sapa, August 2011)

Read more:

Cervical cancer

Anal cancer

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
Eskom has considered continuous load shedding at Stage 2, instead of introducing it when the power system faces a crunch. What are your thoughts?
Please select an option Oops! Something went wrong, please try again later.
Results
I'm all for it - we're going to have power cuts regardless, so we might as well have some stability to better plan our lives
45% - 4174 votes
No thanks! I prefer having periods of no load shedding and we cannot normalise this crisis
55% - 5044 votes
Vote
Rand - Dollar
17.93
-1.8%
Rand - Pound
19.45
-0.0%
Rand - Euro
17.37
-0.0%
Rand - Aus dollar
11.70
-0.0%
Rand - Yen
0.13
-0.0%
Gold
1,643.66
0.0%
Silver
18.87
0.0%
Palladium
2,073.00
0.0%
Platinum
858.50
0.0%
Brent Crude
86.15
-5.0%
Top 40
57,110
-3.1%
All Share
63,417
-2.9%
Resource 10
56,319
-7.5%
Industrial 25
78,436
-1.2%
Financial 15
14,142
-1.6%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE